SCHEMBL18044870

SCHEMBL18044870

NC(=O)c1cc(S(=O)(=O)C2CNCCO2)sc1NC(=O)c1ccco1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 7/20 0.51
▸ ALDH1A1 P00352 6/20 0.51
▸ HPGD P15428 6/20 0.51
▸ MAPT P10636 6/20 0.51
▸ NPC1 O15118 5/20 0.51
▸ RAB9A P51151 5/20 0.51
▸ SMN1; SMN2 Q16637 5/20 0.51
▸ MEN1 O00255 5/20 0.51
▸ KDM4E B2RXH2 4/20 0.51
▸ MAPK10 P53779 2/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ FLT3 P36888 1/20 0.41
▸ CHEK1 O14757 1/20 0.39
▸ IKBKE Q14164 1/20 0.39
▸ TBK1 Q9UHD2 1/20 0.39
▸ TP53 P04637 2/20 0.38
▸ HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18044859 0.83 CHEK1 (0.41) KMT2AMEN1CHEK1IKBKETBK1
SCHEMBL18044883 0.83 CFTR (0.40) ALDH1A1HPGDMAPTALOX15HSD17B10
SCHEMBL18044865 0.83 IKBKB (0.41) KMT2AALDH1A1MAPTNPC1RAB9A
SCHEMBL18044891 0.83 CFTR (0.39) CHEK1CFTR
SCHEMBL18044861 0.81 CHEK1 (0.39) KMT2AMEN1CHEK1CFTR
SCHEMBL18044862 0.81 CFTR (0.39) KMT2AMEN1CHEK1CFTR
SCHEMBL18044877 0.81 CFTR (0.38) ALDH1A1MAPTALOX15HSD17B10CHEK1
SCHEMBL18044866 0.81 CFTR (0.36) ALDH1A1MAPTALOX15HSD17B10CHEK1
SCHEMBL18044890 0.80 CFTR (0.40) CHEK1CFTR
SCHEMBL18044900 0.80 CFTR (0.40) CHEK1CFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9867806-B2 Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis GALAPAGOS NV (BE) 2018-01-16 — — US disclosed
US-20160263084-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS GALAPAGOS NV (BE) 2016-09-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160263084-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC3, ABCC5 KMT2A 3948/4885ALDH1A1 1522/4885HPGD 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback